Investigation Overview
January 31, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Novan Inc (NASDAQ:NOVN) shares over potential securities laws violations by Novan Inc NASDAQ:NOVN and certain of its directors and officers in connection certain financial statements was announced.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Novan Inc (NASDAQ:NOVN) concerning whether a series of statements by Novan Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Shares of Novan Inc (NASDAQ:NOVN) reached as high as $29.06 per in December 2016.
On January 27, 2017, Novan Inc NASDAQ:NOVN) announced top-line results from the Companys two, replicate Phase 3 pivotal clinical trials for SB204 in the treatment of acne vulgaris. Shares of Novan Inc (NASDAQ:NOVN) dropped on January 27, 2017 to as low as $3.52 per share.